Literature DB >> 23087084

miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma.

Gang Shen1, Hongyun Jia, Qiang Tai, Yanhao Li, Deji Chen.   

Abstract

Aberrant activation of the Wnt/β-catenin signal pathway is frequently observed in hepatocellular carcinoma (HCC). β-Catenin is the major cellular effector of Wnt signaling and inactivation of adenomatous polyposis coli (APC) results in nuclear accumulation of β-catenin. Therefore, it was speculated that APC inhibition could play important roles in activating the Wnt/β-catenin pathway and in HCC progression. In this study, we report that miR-106b expression is markedly upregulated in hepatoma cells and hepatoma tissues compared with immortalized normal liver epithelial cells and normal hepatic tissues. Ectopic expression of miR-106b induces the proliferation and anchorage-independent growth of hepatoma cells, whereas inhibition of miR-106b reduced this effect. Furthermore, miR-106b upregulation in hepatoma cells modulated entry into the G(1)/S transitional phase by upregulating cyclin D1 and downregulating APC. Moreover, we demonstrated that miR-106b downregulates APC expression by directly targeting the 3'-untranslated region of APC messenger RNA. Taken together, our results suggest that miR-106b plays an important role in promoting the proliferation of human hepatoma cells and presents a novel mechanism of micro RNA-mediated direct suppression of APC expression in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23087084     DOI: 10.1093/carcin/bgs320

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  43 in total

Review 1.  The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects.

Authors:  Motoyuki Otsuka; Takahiro Kishikawa; Takeshi Yoshikawa; Motoko Ohno; Akemi Takata; Chikako Shibata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2013-11-21       Impact factor: 7.527

2.  miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3.

Authors:  Yi Zhang; Wei Huang; Yan Ran; Yan Xiong; Zibiao Zhong; Xiaoli Fan; Zhenghua Wang; Qifa Ye
Journal:  Tumour Biol       Date:  2015-05-23

Review 3.  microRNA regulation of Wnt signaling pathways in development and disease.

Authors:  Jia L Song; Priya Nigam; Senel S Tektas; Erica Selva
Journal:  Cell Signal       Date:  2015-04-02       Impact factor: 4.315

4.  "Testing your methyl": DNA methylation profiling of serum DNA of HCC patients.

Authors:  Thomas Tu; Nicholas A Shackel; Geoffrey McCaughan
Journal:  Hepatol Int       Date:  2013-09-10       Impact factor: 6.047

Review 5.  Noncoding RNA as therapeutic targets for hepatocellular carcinoma.

Authors:  Joseph George; Tushar Patel
Journal:  Semin Liver Dis       Date:  2015-01-29       Impact factor: 6.115

Review 6.  miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.

Authors:  Weiqi Tan; Yang Li; Seng-Gee Lim; Theresa M C Tan
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

7.  Dicer1 Ablation Impairs Responsiveness of Cerebellar Granule Neuron Precursors to Sonic Hedgehog and Disrupts Expression of Distinct Cell Cycle Regulator Genes.

Authors:  Qian Liu; Mei Jiang; Yi Kuang; Xiaoqiong Shu; Jun Li; Matthew W Li; Hedong Li
Journal:  Cerebellum       Date:  2017-04       Impact factor: 3.847

8.  Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening.

Authors:  Li Jiang; Xue Li; Qi Cheng; Bin-Hao Zhang
Journal:  Tumour Biol       Date:  2015-04-17

9.  miR-106b-responsive gene landscape identifies regulation of Kruppel-like factor family.

Authors:  Cody J Wehrkamp; Sathish Kumar Natarajan; Ashley M Mohr; Mary Anne Phillippi; Justin L Mott
Journal:  RNA Biol       Date:  2018-02-01       Impact factor: 4.652

10.  miR-411 contributes the cell proliferation of lung cancer by targeting FOXO1.

Authors:  Zhiju Zhao; Limei Qin; Shu Li
Journal:  Tumour Biol       Date:  2015-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.